The total return over the past 12 months is -34.63% vs. +16.94% for the S&P 500. So far it's up -48.04% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (34.63%) | (35.47%) | (53.60%) | (32.27%) | N/A | N/A |
| Total Return CAGR | (34.63%) | (35.47%) | (53.60%) | (32.27%) | N/A | N/A |
| Revenue CAGR | (96.72%) | +11.95% | +56.10% | N/A | N/A | N/A |
| Net Income CAGR | (387.97%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Atara Biotherapeutics, Inc. (ATRA)
| Year | Start price | End price | ATRA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $18.09 | $9.40 | (48.04%) | +14.51% | (62.55%) |
| 2025 | $13.31 | $18.09 | +35.91% | +17.72% | +18.19% |
| 2024 | $12.82 | $13.31 | +3.82% | +24.89% | (21.07%) |
| 2023 | $82.00 | $12.82 | (84.37%) | +26.19% | (110.56%) |
| 2022 | $394.00 | $82.00 | (79.19%) | (18.17%) | (61.02%) |
| 2021 | $490.75 | $394.00 | (19.71%) | +28.74% | (48.45%) |
| 2020 | $411.75 | $490.75 | +19.19% | +18.37% | +0.82% |
| 2019 | $868.50 | $411.75 | (52.59%) | +31.22% | (83.81%) |
| 2018 | $452.50 | $868.50 | +91.93% | (4.56%) | +96.49% |
| 2017 | $355.00 | $452.50 | +27.46% | +21.70% | +5.76% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
